Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by jacques.colinge
Group name EquipeJC
Item Type Journal Article
Title Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy
Creator Beziaud et al.
Author Laurent Beziaud
Author Laura Boullerot
Author Thi Tran
Author Laura Mansi
Author Elodie Lauret Marie-Joseph
Author Patrice Ravel
Author Ludger Johannes
Author Jagadeesh Bayry
Author Eric Tartour
Author Olivier Adotévi
Abstract mTOR pathway inhibitors such as rapalogs represent a promising tool to induce functional memory CD8 T cells. In our study, we investigated the combination of temsirolimus with anticancer vaccines. Using various designs of cancer vaccines (short and long peptides or the B subunit of Shiga toxin as an antigen delivery vector) and tumor models (melanoma, lung and colon cancer), we showed that the administration of temsirolimus efficiently decreased tumor growth and enhanced tumor-specific CD8 T-cell responses induced by vaccination. Furthermore, tumor-specific CD8 T cells induced by the bi-therapy (vaccine + temsirolimus) exhibit phenotypic characteristics of central memory (CD127+ CD62L+ ) CD8 T cells compared to vaccination alone. We demonstrated that regulatory CD4 T cells (Tregs ) expansion in vivo limits the efficacy of the bi-therapy by altering the antitumor CD8 T-cell responses. Finally, the use of a small molecule CCR4 antagonist to prevent Tregs induction considerably improved the efficacy of the bi-therapy by enhancing CD8 T cells-mediated antitumor immunity. Taken together, our study highlights the potential interest of combining cancer vaccines with drugs that promote memory CD8 T cells and inhibit Tregs .
Publication International Journal of Cancer
Date Sep 05, 2018
Journal Abbr Int. J. Cancer
Language eng
DOI 10.1002/ijc.31842
ISSN 1097-0215
Library Catalog PubMed
Extra PMID: 30183073
Tags cancer vaccine, CCR4 antagonist, CD8 T cells, original, rapalog, regulatory CD4 T cells
Date Added 2018/11/26 - 18:28:28
Date Modified 2019/05/14 - 21:03:11
Notes and Attachments PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés